Trihexyphenidyl
Brand names: Broflex
Trihexyphenidyl is an antimuscarinic (anticholinergic) agent used in Parkinson's disease, particularly for tremor, and to manage drug-induced extrapyramidal symptoms.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks central muscarinic acetylcholine receptors, helping to redress the relative cholinergic excess that results from dopamine deficiency or dopamine-receptor blockade in the basal ganglia.
Prescribing in practice
- Antimuscarinic effects make it hazardous in the elderly and it should be avoided where there is cognitive impairment, narrow-angle glaucoma, urinary retention or significant prostatic enlargement.
- Confusion, hallucinations, dry mouth, blurred vision and constipation are common, especially in older patients.
- It should be withdrawn gradually rather than stopped abruptly.
Monitoring
Monitor cognition, intraocular pressure where relevant, bowel and bladder function and overall antimuscarinic burden.
Counselling the patient
- Report confusion, hallucinations, eye pain or difficulty passing urine.
- Dry mouth and blurred vision are common; take care with tasks needing clear vision.
Evidence & guidelines
Its role in Parkinsonian tremor and drug-induced extrapyramidal symptoms is long established in clinical practice and standard references.
Reference: NICE NG71 (Parkinson's Disease); British Paediatric Neurology Association Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Rate-Pressure Product (RPP) · Haemodynamics
- DAPT Score · Coronary Artery Disease
- Mehran Score for Post-PCI Contrast Nephropathy · Coronary Artery Disease
- Aortic Dissection Detection Risk Score (ADD-RS) · Aortic Disease
- RoPE Score for Patent Foramen Ovale · Structural Heart Disease
- Canadian Cardiovascular Society (CCS) Angina Grading · Coronary Artery Disease
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS